A patient with arthritis, severe back pain, impaired wound healing, and perforated sigmoid colon

Lancet

Volumn 367, Issue 9527, 2006, Pages 2032-

  Härle, Peter ^a   Schlottmann, Klaus ^a   Ehrenstein, Boris P ^a   Fleck, Martin ^a   Glück, Thomas ^a   Herold, Thomas ^a   Schubert, Thomas EO ^a   Straub, Rainer H ^a   Schölmerich, Jürgen ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; BENZBROMARONE; COLCHICUM EXTRACT; DIPYRONE; PARACETAMOL; PREDNISOLONE; PROBENECID; RASBURICASE;

AGED; ARTHRITIS; ARTICLE; BACKACHE; BACTERIAL PERITONITIS; BIOPSY; CASE REPORT; CAUSE OF DEATH; COLON PERFORATION; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEVER; GOUT; HEMICOLECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERURICOSURIA; ILEOSTOMY; INTERVERTEBRAL DISK DEGENERATION; MALE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; PRIORITY JOURNAL; SIGMOID; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERTEBRA FRACTURE; WOUND HEALING IMPAIRMENT;

EID: 33745003691     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68894-6     Document Type: Article

References (3)

1. Reinders M., van Roon E., Brouwers J., and Jansen T. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?. Ann Rheum Dis 64 (2005) 516
2. Ganson N., Kelly S., Scarlett E., Sundy J., and Hershfield M. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8 (2005) R12
3. Schumacher Jr. H. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 14 (2005) 893-903